Burlington, MA – According to filings with the U.S. Securities and Exchange Commission, CoreMap is raising $27,999,995.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Sarah Kalil played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About CoreMap
CoreMap exists to improve patient outcomes by delivering advanced diagnostic technology to electrophysiologists and patients. Our technologies will allow for patient specific treatments, because when treating the 33 million people with atrial fibrillation, one size does not fit all. Atrial fibrillation (AF) is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications. Normally, your heart contracts and relaxes to a regular beat. In atrial fibrillation, the upper chambers of the heart (the atria) beat irregularly instead of beating effectively to move blood into the ventricles. If a clot breaks off, enters the bloodstream and lodges in an artery leading to the brain, a stroke results. Our technology will allow physicians to see AF and create better treatment options for their patients.

To learn more about CoreMap, visit http://coremapmedical.com/

Contact:
Sarah Kalil, President and Chief Executive Officer
802-233-2032
skalil@coremapmedical.com
https://www.linkedin.com/in/sarah-o-connell-kalil-a027229/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved